Evaluation of Preoperative N1539 in Total Knee Arthroplasty

Exclusion Criteria

• •Have a known allergy or hypersensitivity to any study treatment.
• •Have a history of previous TKA.
• •Has plans for a concurrent surgical procedure (eg, bilateral TKA).
• •Has TKA planned to be performed under general anesthesia.
• •Have a history of myocardial infarction within the preceding 12 months.
• •Have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant condition that would preclude participation.
• •Have active or recent (within 6 months) gastrointestinal ulceration or bleeding.
• •Have a known bleeding disorder which may be worsened with the administration of an NSAID.
• •Be currently receiving treatment with oral meloxicam (Mobic®) or another NSAID within 48 hours prior to surgery.
• •Have previously received N1539/IV meloxicam or received any investigational product within 30 days before dosing with study medication.
• •Have undergone or be expected to undergo radiation therapy, chemotherapy, or other biological therapy for cancer treatment, within 60 days prior to screening through last follow-up.